Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001829126-25-004206
Filing Date
2025-06-03
Accepted
2025-06-03 21:15:31
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 31288
  Complete submission text file 0001829126-25-004206.txt   32988
Mailing Address 295 MADISON AVENUE, SUITE 2400 NEW YORK NY 10017
Business Address 295 MADISON AVENUE, SUITE 2400 NEW YORK NY 10017 813-766-9539
EYENOVIA, INC. (Subject) CIK: 0001682639 (see all company filings)

EIN.: 471178401 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-90395 | Film No.: 251021710
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 11 WEST 42ND STREET, 9TH FLOOR NEW YORK NY 10036
Business Address 11 WEST 42ND STREET, 9TH FLOOR NEW YORK NY 10036 212-878-3523
Avenue Venture Opportunities Fund, L.P. (Filed by) CIK: 0001792691 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A